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Abstract. Hadrontherapy is a high-precision technique in cancer radiation therapy, which allows obtaining
a superior conformal treatment with respect to photons used in conventional radiation therapy. To reach
this ambitious goal without reducing the patient throughput needed in a hospital-based environment, the
physical and radiobiological properties of charged hadrons, protons and carbon ions in particular, have
to be exploited at best, making use of the most modern technologies issued from research in nuclear and
particle physics. In the present days, we are assisting to a continuous technological challenge, leading to
the conception and to the development of innovative methods and instruments. In this paper, the most
relevant challenges in dose delivery systems, gantries, imaging, quality assurance and particle accelerators
are reviewed.
1 Generalities on hadrontherapy
Hadrontherapy —often also denominated “particle therapy”— is a collective word used to indicate the treatment of
tumours through external irradiation by means of accelerated hadronic particles. Several kinds of particles have been
and are the subject of intensive clinical and radiobiological studies: neutrons, protons, pions, antiprotons, helium,
lithium, boron, carbon and oxygen ions. Among all these possibilities, only two of them —protons and carbon ions—
are nowadays used in clinical practice and represent the focus of an ongoing remarkable scientiﬁc and technological
development. For this reason, only proton and carbon ion therapies are discussed in this paper.
Protons and carbon ions are more advantageous with respect to X-rays mainly because of three reasons, two of
which pertain to physics and one to radiation biophysics. The release of energy of charged hadrons along their path
inside the patient’s body is characterized by a large deposit localized in the last few millimetres at the end of their
range, in the so-called Bragg peak region. Here they produce most of the damage to the cells, while sparing both
traversed and deeper located healthy tissues. Moreover, charged hadrons penetrate the patient with minimal diﬀusion
and, using their electric charge, few millimetre FWHM “pencil beams” of variable penetration depth can be precisely
guided towards any part of the tumour. Finally, the ionization properties of light ions are such that they deposit in
a traversed cell much larger energy in the Bragg peak region with respect to protons having the same range. For
carbon ions, a factor 24 more energy is deposited and the produced ionization column is therefore so dense to be able
to induce direct multiple strand brakes in the DNA, thus leading to damages, which are often non-repairable by the
usual cellular mechanisms. This eﬀect is quantiﬁed by an enhancement of the Radio Biological Eﬀectiveness (RBE)
and opens the way to the treatment of tumours, which are resistant to X-rays and protons at the doses prescribed by
standard medical protocols.
In connection with this argument, it has to be stressed that hypoxic tissues are known to be less radiosensitive
than oxygenated ones, so that the presence or absence of oxygen within cells has a strong inﬂuence on the biological
eﬀects of radiation. This eﬀect —which is expressed in terms of Oxygen Enhancement Ratio (OER)— is very much
dependent on the Linear Energy Transfer (LET). For low LET radiation, such as X-rays or protons, hypoxia represents
a serious limitation factor to the eﬀectiveness of the treatment. For high LET, this eﬀect is reduced and carbon ions
represent a powerful tool for the treatment of hypoxic radio resistant tumours [1].
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Fig. 1. General layout of a proton therapy centre featuring one accelerator, three treatment rooms with rotating gantries, one
treatment room with ﬁxed horizontal beams and one room for research activities. The example reported here is based on a
system commercialized by the company IBA (Belgium). The Energy Selection System (ESS) is present only with cyclotrons and
consists on a long magnetic channel, equipped with movable absorbers and slits, needed to vary the energy. (Courtesy IBA.)
Molecular imaging is expected to play an important role in treatment planning in the near future [2] and, in
particular, the detection of hypoxic tumour tissues by means of Positron Emission Tomography (PET) radiotracers
represents a potential tool to tailor at best the therapeutical strategy.
In order to treat deep-seated tumours, maximum depths of the order of 25 cm in soft tissues have to be reached.
This directly translates into the maximum energy of proton and carbon ion beams which has be employed: 200MeV
and 4 500MeV (i.e. 375MeV/u), respectively. As far as beam currents are concerned, the limit is set by the amount
of dose to be delivered to the tissues, typically 2Gy per litre per minute. This translates into beam currents on target
of the order of 1 nA and 0.1 nA for protons and carbon ions, respectively.
The maximum energy and current determine the main characteristics of the accelerator: 4–5 metre diameter
cyclotrons, both at room temperature and superconducting, and 6–8 metre diameter synchrotrons are today in use
for proton therapy while for carbon ion therapy only 20–25 metre diameter synchrotrons are commercially available.
As presented in ﬁg. 1, a modern hadrontherapy centre is based on a complex facility in which the accelerator is
connected to several treatment rooms by means of beam transport lines. The treatment rooms are equipped with ﬁx
beams —usually horizontal but vertical and 45◦ are also in use— and/or rotating gantries, which, for proton therapy,
are about 10m high, 100 tons heavy structures supporting a set of magnets, so that the patient can be irradiated from
any direction, exactly like in conventional X-ray radiation therapy.
The ﬁrst idea of using accelerated protons and ions in cancer radiation therapy dates back to 1946 when R. Wilson
wrote a very illuminating seminal paper [3] in which all the basic principles and potentialities of this discipline are
stated and remarkably discussed, especially if one considers the fact that precise imaging techniques and enough
powerful accelerators were almost a dream at that time. It is interesting to remark that Wilson discussed proton
beams, but mentioned also helium and carbon ions.
The choice of carbon ions was made at the beginning of the nineties and today it is often asked whether other ions,
diﬀerent from protons and carbon, could be beneﬁcial. The answer is clear for ions heavier than carbon, which, being
characterized by a too high LET in the entrance channel and by a too large fragmentation, cannot be considered as
good candidates for cancer therapy. The clinical treatments performed in Berkeley in the seventies with Ne ions clearly
demonstrated that undesirable eﬀects are produced in the traversed and downstream healthy tissues [4]. On the other
hand, the use of ions lighter than carbon —such as helium, lithium and boron— present some potential advantages [5]
and are matter of scientiﬁc debate. With respect to protons, they have less lateral scattering and present a sharper
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distal edge. When compared to carbon ions, they have less fragmentation and a smaller LET in the entrance channel,
which is particularly important for shallow tumours. Moreover, from a technical point of view, they need smaller
accelerators.
2 Present status of hadrontherapy centres
The ﬁrst hadrontherapy treatments took place with proton beams in Berkeley [6] in 1954, followed by Uppsala in 1957.
This pioneering work opened the way to the intense activity performed at the Harvard cyclotron [7] where physicists
and radiation oncologists worked together for many decades on three main clinical studies: neurosurgery for intracranial
lesions (3687 patients), eye tumours (2979 patients) and head-neck tumours (2449 patients). The illuminating results
obtained by the Harvard group represented the basis for many of the successive clinical and technical developments.
A fundamental milestone was accomplished in 1990 when the ﬁrst patient was treated at the Loma Linda Uni-
versity Medical Center in California, the ﬁrst hospital based proton therapy centre [8]. This facility featured the ﬁrst
“corkscrew”-type rotating gantries [9] designed for routine treatment. It has to be remarked that, up to this moment,
all the hadrontherapy facilities were based on existing particle accelerators designed for fundamental research, often
sharing human resources and beam time with other activities. Moreover, some of these centres made use of low energy
—about 70MeV— cyclotrons, in which only the treatment of ocular pathologies was possible. About 14000 patients
have been irradiated, mainly with protons (10243) and helium ions (2054), in the about ten centres, which had all
been built in nuclear or particle physics laboratories and are now closed [10].
In the last twenty years, from being practiced only in specialized research laboratories, proton therapy is becoming
a widely recognized clinical modality in oncology. By the end of 2010, more than 80000 patients have been treated by
proton therapy worldwide, very often aﬀected by pathologies located near critical structures, the so-called organs at risk
(OAR). It is important to remark the importance of proton therapy for paediatric patients, for whom the irradiation of
critical organs may lead to severe permanent consequences on the quality of life and to possible induction of secondary
cancers [11].
As reported in tables 1 and 2, many hadrontherapy centres are nowadays in operation, under construction or in
a phase of advanced project and more than twenty new hospital-based facilities are expected to be operational in
the next ﬁve years, mostly located in USA, Europe and Japan. It is worth stressing the essential contribution to this
development given by the main commercial companies active in this ﬁeld: Hitachi (Japan), IBA (Belgium), Mitsubishi
(Japan), Optivus (USA), Siemens (Germany) and Varian/Accel (USA/Germany).
It is also interesting to remark that more and more centres are “dual”, in the sense that they feature not only
protons but also carbon ions, as discussed in the next section.
3 Therapy with carbon ions
While proton therapy is nowadays considered an established clinical modality, carbon ion therapy is still on its way
to become a commonly accepted treatment option. Due to its speciﬁcity and to the complex radiobiological models
essential for treatment planning, carbon ion therapy is nowadays facing a challenging phase of intense technical research
and clinical trials.
Since the construction of the Heavy Ion Medical Accelerator in Chiba (HIMAC), which treated the ﬁrst patient in
1994, Japan is the most advanced country in carbon ion therapy. By the end of 2009, about 5000 patients have been
treated and many radio resistant tumours have been shown to be controllable.
In Europe, treatments started at the “pilot project” for carbon ion therapy at GSI in Germany in 1997. Since then,
about 400 patents have been treated and this project lead to the construction of the ﬁrst European hospital-based
centre in Heidelberg (HIT). This new centre features a gigantic 600 tons, 25 metre long carbon ion gantry (see ﬁg. 5,
left) —the only one constructed so far— and treated the ﬁrst patient in November 2009.
In 1995 one of us (UA) proposed (in collaboration with Mainard Regler, promoter of the MedAustron project)
to the CERN management to initiate the Proton Ion Medical Machine Study (PIMMS), centred on the design of a
synchrotron and a system of beam lines optimized for the treatment of deep seated tumours with collimated beams
of carbon ions, protons and other light ions. From 1996 to 2000 the study was carried out under the direction of
Phil Bryant with the help of many part-time staﬀ members of CERN and with essential contributions from TERA
(Italy), Med-AUSTRON (Austria) and Oncology 2000 (Czech Republic) [12]. From the PIMMS study, the TERA
design of the Centro Nazionale di Adroterapia Oncologica (CNAO) has been completed and passed in 2004 to the
CNAO Foundation, which —in collaboration with INFN— has completed its construction in 2010 in Pavia. The
CNAO will be the second hospital-based centre for proton and carbon ion therapy in Europe. Two more centres are
under construction in Germany, in Marburg and Kiel, by the company Siemens, which has obtained the know-how
and the patents from GSI. MedAustron in Austria has recently acquired the drawings of CNAO to build in Wiener
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Table 1. Hospital-based hadrontherapy facilities in operation at the end of 2010 [10].
Max.
Start TotalPart. clinical Beam
of treated
Date ofCentre Country
acc. energy direction(a)
treat. patients
total
(MeV)
ITEP, Moscow Russia p, S 250 H 1969 4226 Dec-10
St.Petersburg Russia p, SC 1000 H 1975 1362 Dec-10
PSI(b) Switzerland p, C 72 H 1984 5458 Oct-10
Dubna(c) Russia p, SC 200 H 1999 720 Dec-10
Uppsala Sweden p, C 200 H 1989 929 Dec-08
Clatterbridge(b) England p, C 62 H 1989 2021 Dec-10
Loma Linda USA p, S 250 3 G, H 1990 15000 Jan-11
Nice(b) France p, C 65 H 1991 4209 Dec-10
Orsay(d) France p, C 230 G, H 1991 5216 Dec-10
iThemba Labs South Africa p, C 200 H 1993 511 Dec-09
MPRI(2) USA p, C 230 2 G, H 2004 1145 Dec-10
UCSF(b) USA p, C 60 H 1994 1285 Dec-10
HIMAC Japan C, S 800/u H, V 1994 5497 Aug-10
TRIUMF(b) Canada p, C 72 H 1995 152 Dec-10
PSI(e) Switzerland p, C 250 G 1996 704 Dec-10
GSI Germany C, S 430/u H 1997 440 Dec-10
HZB (HMI), Berlin(b) Germany p, C 72 H 1998 1660 Dec-10
NCC, Kashiwa Japan p, C 235 2 G, H 1998 772 Dec-10
HIBMC, Hyogo Japan p, S 230 2 G, H 2001 2382 Nov-09
HIBMC, Hyogo Japan C, S 320/u H, V, 45◦ 2002 638 Nov-09
PMRC(2), Tsukuba Japan p, S 250 2 G, H 2001 1849 Dec-10
NPTC, MGH, Boston USA p, C 235 2 G, H 2001 4967 Dec-10
INFN-LNS,Catania(b) Italy p, C 60 H 2002 174 Mar-09
Shizuoka Japan p, S 235 2 G, H 2003 986 Dec-10
WERC,Tsuruga Japan p, S 200 H, V 2002 62 Dec-09
WPTC, Zibo China p, C 230 3 G, H 2004 1078 Dec-10
MD Anderson Cancer Center,
USA p, S 250 3 G, H 2006 1700 Dec-09
Houston(f)
UFPTI, Jacksonville USA p, C 230 3 G, H 2006 2679 Dec-10
NCC, IIsan South Korea p, C 230 2 G, H 2007 648 Dec-10
RPTC, Munich(g) Germany p, C 250 4 G, H 2009 446 Dec-10
ProCure, Oklahoma USA p, C 230
G, H, 2
2009 21 Dec-09H/60◦
HIT, Heidelberg Germany p, S 250 2 H, G 2009
Treatment
Nov-09started
HIT, Heidelberg Germany C, S 430/u 2 H, G 2009
Treatment
Nov-09
started
U. Pennsylvania,
USA p, C 230 4 G, H 2010 150 Dec-10Philadelphia
GHMC, Gunma Japan C, S 400/u 3 H, V 2010
Treatment
Mar-10
started
IMPCAS, Langzou China C, S 400/u 1 H 2009 126 Dec-10
CDH, Warrenville USA p, C 230
G, H,
2010
Treatment
Oct-102 H/60 started
IFJ PAN, Krakow(b) Poland p, C 60 H 2011 9 Apr-11
Total protons 68144
Total C-ions 6701
Total 74845
(a)
Horizontal (H), vertical (V), gantry (G), inclined (ex. 45◦).
(b)
Ocular tumours only.
(c)
Degraded beam.
(d)
3676 ocular tumours; previously SC; new cyclotron and gantry since Nov-10.
(e)
Degraded beam from 1996 to 2006; dedicated 250MeV proton beam from 2007. Scanning beam only.
(f)
With spread and scanning beams (since 2008).
(g)
Scanning beam only.
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Table 2. Hospital-based hadrontherapy facilities in planning or under construction at the end of 2010 (main source [10]).
Location Country Particle
Max. energy
Beams(a) Rooms
Foreseen start
(MeV) - acc. date
PSI, Villigen Switzerland p
250 1 G additional
3 2011 (Gantry2)
SC cyclotron to 1 G, 1 H
WPE, Essen Germany p
230
3 G, 1 H 43 2011
cyclotron
CNAO, Pavia Italy p, C
430/u
2 H, 1 H+V 3 2011
synchrotron
PTC, Marburg Germany p, C
430/u 3 H,
4 2011
synchrotron 1 OB
Chang Gung
Taiwan p
235 4 G,
4 2011
Memorial Hospital cyclotron 1 H (research)
PTC, Fukushima Japan p
230
2 G, H 3 2011
cyclotron
ProCure, Chicago USA p
230
2 H, 2 H+V 4 2011
cyclotron
HUPBTC,
USA p
230
4 G, 1 H 5 2011
Hampton cyclotron
PMHPTC,
Russia p
250
1 H 1 2011
Protvino cyclotron
Medipolis,
Japan p
250
3 G 3 2011
Kagoshima synchrotron
NRoCK, Kiel Germany p, C
430/u 1 H, 1 V+OB,
3 2012
synchrotron 1 H+V
250
2 G,
NIPTRC, Chicago USA p
SC cyclotron
2 H 4 2012
1 H (research)
Barnes Jewish, St.
250
Louis
USA p single room SC 1 G 1 2012
synchrocyclotron
PTC
Czech
p
230
3 G, H 4 2013
Republic cyclotron
HITFil, Lanzhou China C
400/u
4 H, V, OB 4 2013
synchrotron
ATreP, Trento Italy p
230
1 G, 1 H 2 2013
cyclotron
Skandionkliniken,
Sweden p
250
2 G, 2 2013
Uppsala Cyclotron
Scripps Proton
250 3 G,
Therapy Center, USA p
SC cyclotron 2 H
5 2013
San Diego
Med-AUSTRON, 400/u
1 G (p only),
Wiener Neustadt
Austria p, C
synchrotron
1 V, 3 2014
1 V+H
iThemba Labs South Africa p
230
1G, 2 H 3 ?
cyclotron
RPTC, Koeln Germany p
250
4 G, 1 H 5 ?
SC cyclotron
CCSR, Bratislava
Slovak
p
72
1 H 1 ?
Republic cyclotron
CMHPTC
Slovak
p
250
1 H 1 ?
Republic synchrotron
SJFH, Beijing China p 230 cyclotron 1 G, 1 H 2 ?
Shanghai China p, C
430/u 1 H, 1 V+OB,
3 ?
synchrotron 1 H+V
ETOILE, Lyon France p, C ? ? ? ?
(a) Horizontal (H), 90◦ vertical (V), 45◦ oblique (OB), rotating gantry (G).
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Fig. 2. In “passive spreading”, the beam is widened and ﬂattened by means of scatterers and adapted to the volume to be
irradiated by means of personalized collimators and compensators. Diﬀerent penetration depths are superimposed by means of
a range shifter to obtain the Spread Out Bragg Peak (SOBP) covering the tumour.
Neustadt a dual centre. In France, Etoile in Lyon is now in the tendering phase while IBA is developing an innovative
superconducting cyclotron (see later) for carbon ion therapy in the framework of the Archade Project in Caen (France).
Thus, in a few years, several hospital based centres for carbon ion therapy will be operational and will produce,
through Phase III trials, the necessary knowledge needed to apply this modality only to the tumours which need it.
For about ﬁfteen years, hadrontherapy is facing a deep change which is bringing a relatively small scientiﬁc com-
munity into a much larger multidisciplinary contest in which medicine, physics, biology, engineering, law, management
and ﬁnance came together and play essential and complementary roles. The large size of these projects, costing 100–200
million Euro, has a big impact not only on the scientiﬁc and technological side but also on the ﬁnancial, logistic and
management aspects. Needles to say that in the construction of a hadrontherapy centre all the details have to be care-
fully evaluated since the very beginning by a solid multi-competence project team capable of facing the unavoidable
problems and compromises.
Two main forces —not always pointing towards the same direction— are driving the developments of this discipline.
On the one hand, to be competitive with the continuously increasing performances of conventional radiation therapy,
innovative tools and techniques are needed to exploit at best the higher potential of hadron beams. On the other
hand, to be able to oﬀer this treatment modality to a large number of patients with cost-eﬀective throughput, the
cost, the size and the complexity of the equipment have to be reduced. To face these challenges, many scientiﬁc and
technological developments are ongoing and new ideas are appearing at the horizon.
4 Challenges in dose delivery systems
The dose delivery system represents a key issue in the treatment process since it allows the transformation of the
beam coming out from the accelerator into a clinical three-dimensional dose distribution, which has to comply with
the medical prescription.
Up to the present and in almost all the centres, the “passive spreading” method —presented in ﬁg. 2— is used.
Although relatively simple, this method requires the construction of personalized “compensators” and, often, “colli-
mators” and does not allow exploiting at best the ballistic properties of charged hadron beams. In particular, extra
doses are produced at the edges of the tumour.
To avoid this, “active” delivery systems are needed. Two innovative techniques have been developed at PSI (protons)
and GSI (carbon ions) to “paint” the tumour by means of a small “pencil beam” driven by magnetic forces and without
the use of any passive device, as presented in ﬁg. 3.
The PSI “spot scanning” [13] technique and the GSI “raster scanning” technique [14] provide very conformal
dose distributions. By the superposition of non-uniform dose distributions coming from many directions, they al-
low very complex treatments by Intensity Modulated Particle Therapy (IMPT). Scanning techniques are nowadays
becoming mature and commercial companies are oﬀering this modality, often in parallel with the standard passive
spreading.
To fully exploit the potentialities of scanning and IMPT, a new dedicated gantry is under commissioning at PSI
since the beginning of 2011. The “Gantry 2” [15] scans the tumour with parallel beams in a two-dimensional surface
and rotates only by 180◦ to allow an easier access to the patient with a more compact structure. The possibility to use
X-rays parallel to the proton beam and passing through a special aperture in the 90◦ magnet is foreseen to optimize
the treatment of moving organs.
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Fig. 3. Developed at PSI, the “spot scanning” technique consists in chopping the beam from a cyclotron to obtain discrete dose
spots of given energy and direction which are used to form a uniform dose distribution (left). Developed at GSI, the “raster
scanning” is based on the use of a pencil beam to paint continuously a slice of the tumour. The irradiation of successive slices,
corresponding to diﬀerent beam energies, gives a three-dimensional uniform dose distribution (right). (Courtesy of PSI and
GSI.)
Fig. 4. The feedback system —studied numerically and experimentally at GSI— compensates for the movements of the organs
acting, with two bending magnets, to correct the transverse movements and, with absorbers of variable thickness, to compensate
for longitudinal movements. (Courtesy GSI.)
It has to be remarked that most of the tumours treated so far by particle therapy —like for example head and neck
cancers— are not subject to motion due to respiration. The treatment of moving organs, like the lung, represents an
important challenge and a very actual theme of research. In Japan, a synchronization “gating” between the beam and
the patient’s respiration is used since long and the irradiation takes place only when the tumour is in the appropriate
position [16]. More sophisticated techniques of active compensation are under study at GSI where the realisation of an
on-line feedback system will allow the change of position and energy of the beam to correct for organ motion eﬀects
(ﬁg. 4). In general, if the tumour target is “painted” only once, organ motion represents a severe inconvenience since
any non-compensated movement can cause important local under-dosages or over-dosages.
Three strategies have been considered to reduce organ motion eﬀects. In order of increasing complexity they are:
i) as mentioned above, in the irradiation of the thorax and the abdominal region the dose delivery is synchronized
with the patient expiration phase (respiratory gating);
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Fig. 5. The only carbon ion gantry constructed so far for the HIT centre in Heidelberg (left) and the project for a carbon/proton
non-scaling FFAG isocentric gantry (right).
ii) the movement of the target is detected by a suitable system, which outputs in real-time its 3D position, and a set
of feedback loops compensate for the predicted position in the dose delivery plan with on-line adjustments of the
transverse and longitudinal locations;
iii) the tumour —continuously tracked as in point ii)— is painted many times in three dimensions so that not only
the movements of the organs (if not too large) can be followed but also any under-dosage or over-dosage can be
compensated during a following pass (multi-painting).
As far as the system which tracks the tumour target is concerned, there are various technical solutions and many
others are under development, mainly in relation to conventional X ray therapy. These techniques include on-line
ﬂuoroscopy, ultrasounds, markers ﬁxed on the body and looked at by infrared cameras [17], on-line imaging of the
patient skin combined with biomechanical models of the respiration [18].
The use of Magnetic Resonance Imaging (MRI) to reduce target-positioning errors in radiation therapy is developing
very fast and open magnet MRI scanners have been proposed for Image Guided Proton Therapy (IGPT) [19]. With
respect to conventional MRI scanners, open magnets allow more comfort for the patient and, when used in radiation
therapy, allow the terapeutical beam to reach the patient with minimal limitations. One problem of this technique
is that tissue-air-bone transitions cause large magnetic ﬁeld inhomogeneities. Images can be therefore distorted with
severe artefacts on the guiding algorithms and, consequently, on the dose distributions. Correction procedures are
under study and corrected images have been produced at a rate of 8ms or less, making MRI-guided particle therapy
very attractive [20].
An optimal delivery system should be based on an eﬀective measuring device and should allow the use of any
combination of the above mentioned three approaches: respiratory gating, active angular/energy feedbacks and multi-
painting. This is one of the most important frontiers of particle therapy [21].
5 Challenges in ion gantries
Due to the three times higher magnetic rigidity with respect to protons, a conventional magnet ion gantry is necessarily
very big, like the one constructed at HIT (ﬁg. 5, left). To make carbon ion gantries more compact, the use of super-
conductivity has been under study since some time. Recently, in the framework of the European Network for Light
Ion Therapy (ENLIGHT) [22], two projects have been ﬁnanced: PARTNER and ULICE. In each of them a Working
Package is devoted to the study the feasibility and development of innovative lightweight rotating delivery systems,
speciﬁcally optimized for a clinical environment. The aim of the work packages is to analyze the various aspects that
inﬂuence the design of a carbon ion gantry and to produce a design of the device. Both medical/functional and tech-
nological issues are considered to obtain a design that controls costs without limiting signiﬁcantly the functionalities.
One of the main challenges here is the depth scanning of the tumour target, which in a normal proton gantry is
made by reducing the ﬁeld by about 10mT in about 100ms, corresponding to about 5mm on the residual range. This
rapid ﬁeld variation is not feasible in a superconducting magnet. Moreover, the good ﬁeld region is much smaller in
a superconducting magnet than in a normal one. This limits the use of scanning magnets located upstream of the 90◦
bending magnet and favours the “downstream” solution, which in turn requires gantries of larger radii.
A few years ago a gantry based on a more “exotic” beam transport technique has been proposed: the Fixed Field
Alternating Gradient (FFAG) gantry [23], shown in ﬁg. 5. This apparatus is relatively light and is characterized by a
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Fig. 6. SAMBA (Strip Accurate Monitor for Beam Applications) is composed by two orthogonal 2mm strip ionization chambers
(left). This detector, in use at PSI, is capable to monitor on-line the beam intensity and the transverse position with sub-
millimetric precision during spot scanning (right).
very large momentum acceptance, which would allow good scanning capabilities. This is an important feature in the
case of fast cycling accelerators, as linacs and FFAGs, in which the energy can be adjusted every few milliseconds.
6 Challenges in imaging and quality assurance
In modern radiation therapy imaging is essential and Computed Tomography (CT) is the basis of treatment planning.
In the near future, the role of MRI and PET functional imaging will surely acquire more importance. In particular,
innovative molecules [24] for PET imaging are nowadays in a phase of advanced study and will provide fundamental
information for treatment planning on hypoxia and on the localization of tumours, which are almost invisible to CT [2].
On-line monitoring of the hadron beams during treatment is of paramount importance for quality assurance. Many
interesting developments in the ﬁeld of particle detectors have been performed in the last years, as the innovative
pad ionization chambers developed for CNAO by INFN-Torino and TERA Foundation [25]. In the same framework,
strip ionization chambers have been built for CPO in Orsay and for the Gantry 2 of PSI [26] (ﬁg. 6, left). As shown
in ﬁg. 6 (right), these chambers allow on-line control of the intensity of the beam and of its position and shape with
sub-millimetric precision.
In radiation therapy, the control of the dose distribution delivered to the tumour target relies on oﬀ-line dosimetry
and not on direct on-line measurements. At GSI, an innovative technique [27] —in-beam PET (ibPET)— has been
developed exploiting the fact that carbon ions produce 11C and 15O nuclei by interacting with the nuclei of the patient’s
body (ﬁg. 7).
Since 11C and 15O are positron emitters, their distribution can be measured —by means of a PET camera installed in
the treatment room— and compared with the treatment planning. Studies are underway also to exploit this technique
for proton-therapy [28] and by using an ordinary PET camera with which the patient is scanned right after the
treatment.
This technique produces images related to the delivered dose, but, unfortunately, is aﬀected by three problems.
Firstly, the number of the electron-positron annihilations is small (of the order of 300 s−1 cm−3), so that the patient
has to remain in the treatment room few minutes after the end of the irradiation to increase the statistics. Secondly,
during this time, the activity is washed out by the blood ﬂow. Finally, the accidental rate, due to the Compton eﬀect
of the 511 keV photons, is large. To avoid this last inconvenient, cheap detectors of large area, which can measure the
time of ﬂight with less than 100 ps time resolution (TOF-PET), are under development [29].
To overcome the disadvantage of PET methods being caused by the half-lives of the positron emitters and sub-
sequent blood ﬂow washout, the detection of prompt radiation components following nuclear reactions between the
incoming particles of the therapeutic beam and the nuclei of the tissues represents a promising modality. Evidently,
metabolic processes do not inﬂuence the spatial distribution of these components. Potentially useful radiation modal-
ities are prompt single γ-rays, light charged particles and neutrons. Published experimental investigations indicate
that the distribution of single γ-rays reﬂects the range distribution of the primary ions [30].
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Fig. 7. The treatment room at GSI equipped with the on-beam PET detector (left). Measured and simulated data demonstrate
that the dose released by carbon ions is eﬀectively conform with respect to the treatment planning. (Courtesy GSI.)
Scintigraphy imaging of single photons is widely applied in nuclear medicine and prompt gamma radiation seems
to have a good potential for in vivo therapy monitoring. However, to exploit prompt gamma radiation, novel imaging
devices —not common in scintigraphy— are needed because of the broad energy spectrum of the γ-rays (0 < E ≤
10MeV). The detection of protons or other light charged particles created via nuclear reactions is technologically less
challenging. However, protons experience, in contrast with respect to high-energy photons, a high stopping power,
which severely limits their possible use. In practice they can be detected only when the incoming beam is made of
carbon ions [29]. All these techniques are under study in the framework of the EU funded ENVISION project [22].
7 Proton radiography
A crucial issue of hadrontherapy is the knowledge of the range, which directly determines the precision of the method.
To completely exploit the ballistic properties of charged hadrons, the determination of the location of the Bragg peak
in the patient body is essential for an optimized treatment planning, both in terms of patient positioning and of dose
distribution inside the patient. Presently, the density of the electrons in the tissues is determined from the greyness
of properly calibrated Computed Tomography (CT) images and then introduced in the Treatment Planning System
(TPS). CT data have necessarily to be corrected to obtain proton ranges, which depend on the density of the traversed
material.
An image obtained with protons traversing the patient body —the so-called proton radiography— is the best
instrument to calibrate precisely the electron density obtained from CT images. Proton radiography can also be used
to perform in a few seconds in situ imaging for patient positioning veriﬁcation before the treatment while giving a
negligible dose to the patient.
Proposed at the end of the sixties [31] as an imaging technique, proton radiography has the drawback of a poor
spatial resolution due to multiple Coulomb scattering and energy straggling. For this reason and because of the need
of a complex installation to produce high-energy proton beams, which can traverse the patient body, this technique
was almost abandoned after the ﬁrst pioneering studies in favour of other imaging techniques.
A renewed interest on proton radiography has been triggered by the present world-wide development of proton
therapy centres and, following the studies performed at the Paul Scherrer Institute (PSI) [32], many projects are
underway in Europe and USA, mostly based on solid state detector trackers followed by a calorimeter to assess the
residual energy.
A diﬀerent system consisting of a set of position-sensitive Gas Electron Multiplier (GEM) detectors and a scintillator
stack read out by solid-state sensors is proposed and developed by the TERA Foundation [33]. On-line images of a
PMMA phantom with holes ranging from 1 to 10mm diameter and form 5 to 15mm depth have been obtained
(ﬁg. 8, left).
To avoid the use of complex and expensive electronic detectors, an alternative method based on nuclear emulsion
ﬁlms interleaved with tissue equivalent absorbers has been recently proposed [34]. After the development and the
scanning of the emulsions —which allows the reconstruction of the proton tracks— proton radiography images can
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Fig. 8. Proton radiography images obtained with GEM detectors followed by a proton range detector (left) and with nuclear
emulsion ﬁlm detectors (right).
be obtained (ﬁg. 8, right), with comparable resolution with respect to the other methods. This technique has the
disadvantage of not producing on-line images but represents a simple and eﬀective tool for the characterization of
proton beams in the commissioning phase of proton therapy clinical facilities.
8 Challenges in particle accelerators
Contrary with respect to conventional radiation therapy, where each treatment room is equipped with a linac, only
one radiation source is available in a hadrontherapy facility. For this reason, the choice of the particle accelerator is of
paramount importance and its up-time represents a very critical issue.
At present, four commercial companies oﬀer proton accelerators —IBA and Varian oﬀer a normal and a supercon-
ducting cyclotron, respectively, while Hitachi and Mitsubishi oﬀer synchrotrons. For carbon ion therapy the commercial
solutions are the synchrotrons proposed by Siemens (Marburg, Kiel and Shanghai) and Mitsubishi (Hyogo, Gunma).
Cyclotrons are characterized by a beam of ﬁxed energy which has to be degraded with passive absorbers in the
ﬁrst part of the beam line —in the so-called Energy Selection System (ESS) of ﬁg. 1— and, with respect to the human
breathing cycle, present a continuous beam, advantageous for the treatment of moving organs with both feedback and
multipainting.
On the other hand, the beam of a synchrotron presents a cycle —the so-called “spill”— which lasts 2–3 seconds
and in which the beam is present for about 1 second. The energy can be varied from spill to spill and no movable
absorbers and ESS are needed. The time structure of a synchrotron is similar to the human respiratory cycle and —in
the absence of a feedback system— requires the gating of the extracted beam in coincidence with the expiratory phase
when moving organs are treated.
For carbon ion therapy, the superconducting cyclotron, which is being built by IBA for the Archade project, has
been designed in collaboration with the Joint Institute for Nuclear Research (JINR) in Dubna [35] and is based on the
“old” 235MeV IBA normal cyclotron for proton therapy. 12C6+ and other ions with a charge to mass ratio of 1/2 are
accelerated to 400MeV/u and extracted by a deﬂector. In particular, this machine can be used for accelerating 4He2+,
6Li3+ and 10B5+. For proton therapy, H2+ molecules are accelerated to 260MeV/u and extracted by stripping. As
for all cyclotrons, the energy is ﬁxed and a 18 meter long ESS is needed to produce a clinical carbon beam in which
all the produced fragments are no more present. The activation of this system and the produced secondary radiation
represent a challenging issue.
In the last ten years Fixed Field Alternating Gradient accelerators (FFAGs) have been the focus of great interest
because of their potentialities in the acceleration of the large currents needed for the future neutrino factories. Hadron-
therapy requires nanoampere currents and a priori a FFAG does not look like the right instrument. Still many designs
have been proposed because of another advantage with respect to cyclotrons and synchrotrons: the possibility of pro-
ducing a high repetition rate beam having a diﬀerent energy every 1–2 milliseconds, which allows a three-dimensional
scanning of the target.
In Japan, a 150MeV proton FFAG has been built [36]. It has very wide magnets because it is of the “scaling” type,
which means that during the acceleration the wiggling orbit increases in average radius but maintains the same shape.
“Non scaling” FFAGs require magnets which are smaller in the radial direction but have the inconvenient that, during
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Fig. 9. The carbon ion depth dose distribution when the number of the active accelerating modules of the linac is varied one
by one. To avoid superposition, a diﬀerent normalization is used for each curve.
acceleration, many resonances are necessarily crossed and the beam dynamics is very delicate. An electron prototype
—called EMMA— is being tested at the Daresbury Laboratory in the UK [37]. A challenging project is proposed by
Keill, Sessler and Trbojevic and is based on three concentric non-scaling FFAGs. This system is surely interesting but
subject to many unknowns, in particular for the injection and the extraction of the beams [38].
Injection and extraction are not a problem for linacs, which, as FFAGs, are fast cycling accelerators in which the
energy of the accelerated beam can be varied continuously within a couple of milliseconds. The “cyclinac” concept,
i.e. the combination of a high-frequency linac (having the standard 3GHz frequency) and a 30MeV cyclotron injector,
has been proposed in 1993 by one of us (UA) [39]. A 3GHz standing wave 1 meter long module has been constructed
and accelerated protons from 62 to 73MeV [40].
CABOTO (CArbon BOoster for Therapy in Oncology) is the application of the same principle to the acceleration
of carbon ions to the energy of 400MeV/u [41]. A possible set-up consists on a 150MeV/u cyclotron, which accelerates
H2+1 and C+6 ions with the linac that boosts them to the required energies with a 30MV/m average acceleration
gradient [42]. Experimental tests are under way to choose the operating frequency between 3GHz and 5.7GHz.
The energy can be varied from spot to spot (ﬁg. 9) and the tumor target can be scanned in three dimensions (i.e.
transversally and also along the beam direction) with a high repetition rate (300–400Hz).
Figure 10 shows a dimensional comparison among the diﬀerent accelerators used and/or proposed for carbon ion
therapy [41].
An important remark: the psychological and economical burden for the patient and the health service can be
minimized by using a carbon ion beam for a 4–5 session “boost” to be delivered in one week before the conventional
treatment, which can then be performed —together with the necessary follow-up— in the radiotherapy department
close to the patient’s home. As already mentioned, this radiotherapy modality is today the theme of clinical investi-
gations on speciﬁcally selected tumours.
9 Proton single-room facilities
The need to reduce size, cost and complexity of hadrontherapy centres may bring a deep change of the entire discipline
in the next future thanks to the development of single-room facilities.
An interesting solution based on a compact synchrotron (5m diameter and 15 tons) with a horizontal beam sent
to a single treatment room is proposed by ProTom [43].
A second line of development concerns single-room proton facilities with a rotating beam. The logic can be best
appreciated by browsing table 3 [41], which has been constructed by using the results of the epidemiological studies
performed in Austria, France, Italy and Germany in the framework of the EU funded network ENLIGHT [44]. They
can be summarized by saying that in the medium-long term about 12% (3%) of the patients treated with high-energy
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Fig. 10. Dimensional comparison of the cyclinac solution with the European carbon ion accelerators.
Table 3. Estimate of the number of X-ray and hadron treatment rooms [41].
Av.
Radiation
Patients per number of Sessions/d Patients/y Rooms per
Relative
treatment
year in 107 sessions in 1 room in 1 room 10 million
ratio
inhabitants per (d = 12 h) (y=230 d) people
patient
Photons 20000 30 48 370 54 82
Protons (12%) 2400 24 36 345 7.0 8
C ions (3%) 600 12 36 690 0.87 1
photons would be better cured with fewer secondary eﬀects if they could be irradiated with proton (carbon ion)
beams.
The table presents the number of treatment rooms needed in ﬁve/ten years for a population of 10 million people
living in a developed country. For proton therapy in the long term a more ﬂexible and patient-friendly solution will
be the one based on a single-room proton accelerator/gantry system, which is constructed on a relatively small area
(≤ 500m2) attached to an existing hospital building. Small (large) radiotherapy departments run 1–2 (5–6) electron
linacs so that, typically, 8 conventional rooms are present in 3–4 hospitals covering a population of 1.5–2 millions. The
single-room proton facility will be attached to one of these hospitals but serve also the others.
The most advanced solution is the single-room facility under development by Still River Systems in collaboration
with MIT [45]. This apparatus is based on a very compact 250MeV superconducting synchrocyclotron designed to ﬁt
in a single treatment room and rotate around the patient. The ﬁxed energy output beam will be pulsed at 200Hz. Of
course, as in the case of cyclotrons, movable absorbers are needed to adjust the proton beam energy and, since passive
spreading is proposed, the dose distribution is not optimal (see ﬁg. 2). The shielding of the patient from the neutrons
produced in the close-by absorbers is a challenging problem, together with the possibility of implementing scanning
pencil beams. In 2009, the 9 T niobium-tin superconducting magnet has been tested and the 15 tons synchrocyclotron
assembled. The ﬁrst beams have been extracted in 2010 and the company foresees the installation of the ﬁrst two
systems in the near future.
The company IBA is developing an innovative single room proton therapy facility named Proteus One [46]. This
solution foresees a 230MeV superconducting synchrocyclotron with a repetition rate of 1000Hz directly connected
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Fig. 11. TULIP (Turning LInac for Prototherapy) is a linac-based single-room proton therapy facility optimized for fast cycling
spot scanning.
with a compact gantry in which the ESS is embedded. The gantry is capable of a 220◦ rotation around the patient to
allow some redundancy with respect to a 180◦ rotation and is optimized for pencil beam scanning and multipainting.
Two further projects, which should produce proton beams rotating around the patient, are under study.
The Lawrence Livermore National Laboratory (LLNL), in collaboration with Tomotherapy and CPAC, is developing
the Dielectric Wall Accelerator (DWA), which accelerates protons in a non-conducting beam tube (the dielectric wall)
energized by a pulsed power system. DWA is an induction accelerator. A classical induction accelerator is made of
modules, containing ferro-magnetic cores, which —powered in sequence— accelerate large currents with gradients
of the order of 100MV/m [47]. Open problems of this scheme are the focusing of the accelerated protons and the
practical feasibility of a 100MV/m gradient, which would allow having the DWA rotating around the patient in a
small single-room facility.
TERA has proposed TULIP (Turning LInac for Prototherapy) as eﬀective response to the above-discussed
needs [48]. This apparatus consists on a cyclotron used as the injector of a system composed by high-frequency
and high-gradient linacs mounted on a rotating structure. The version presented in ﬁg. 11 is based on a 5.7GHz
standing-wave linac producing a bunched beam at 50–150Hz directed towards the patient while the gantry rotates
and the proton energy is adjusted —from one pulse to the next, if needed— in a 110–200MeV energy range. Making
use of all the advantages of a linac [21], the dose is delivered by scanning by means of two transverse magnetic ﬁelds
to an area equal to 20 × 20 cm2. The active delivery system is similar to the one of a helical Tomotherapy, with the
advantage of a much better sparing of the healthy tissues surrounding the tumour target. TULIP presents many tech-
nological challenges, such as the mechanical structure, the beam transport through diﬀerent accelerating structures
and the distribution of the radio-frequency (RF) power to the rotating linacs.
Looking into the very far future, the acceleration of protons and ions by means of laser plasma devices represents
a fascinating ﬁeld of research. It has to be remarked that, at present, only the maximum energy of 67.5MeV for
protons has been very recently achieved [49]. Despite the large eﬀorts and progress in this ﬁeld, protons are produced
with a very wide energy spread peaked at low energies, making of the dose distribution system a very diﬃcult
challenge [50].
10 Outlook
Since its beginnings, nuclear and particle physics have oﬀered medicine and biology tools and techniques to study,
detect and cure cancer. Hadrontherapy represents today their major contribution to the cure of patients and many
interesting developments, at the forefront of science and technology, are in progress. Further challenging innovations
are appearing at the horizon, assuring a very exciting time to the future of this discipline.
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